These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26344591)

  • 1. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors.
    Machado VA; Peixoto D; Costa R; Froufe HJ; Calhelha RC; Abreu RM; Ferreira IC; Soares R; Queiroz MJ
    Bioorg Med Chem; 2015 Oct; 23(19):6497-509. PubMed ID: 26344591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
    Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
    ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-aryl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as VEGFR-2 tyrosine kinase inhibitors: synthesis, biological evaluation, and molecular modelling studies.
    Soares P; Costa R; Froufe HJ; Calhelha RC; Peixoto D; Ferreira IC; Abreu RM; Soares R; Queiroz MJ
    Biomed Res Int; 2013; 2013():154856. PubMed ID: 23936775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
    Thompson AM; Delaney AM; Hamby JM; Schroeder MC; Spoon TA; Crean SM; Showalter HD; Denny WA
    J Med Chem; 2005 Jul; 48(14):4628-53. PubMed ID: 16000000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors.
    Shi L; Zhou J; Wu J; Cao J; Shen Y; Zhou H; Li X
    Bioorg Med Chem; 2016 Apr; 24(8):1840-52. PubMed ID: 26968648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrimidinylacetamide-based 2-pyridylureas as Angiogenesis Inhibitors: Design, Synthesis and Biological Evaluation.
    Deng YH; Yan ZH; Liu JP; Liu Y; Sun LP
    Arch Med Res; 2017 May; 48(4):333-342. PubMed ID: 28882321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic 1-Aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas Inhibit MCF-7 and MDA-MB-231 Human Breast Cancer Cell Lines Through PI3K/Akt and MAPK/Erk Pathways.
    Machado VA; Peixoto D; Queiroz MJ; Soares R
    J Cell Biochem; 2016 Dec; 117(12):2791-2799. PubMed ID: 27152982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: design, synthesis and biological evaluation.
    Wang C; Gao H; Dong J; Zhang Y; Su P; Shi Y; Zhang J
    Bioorg Med Chem; 2014 Jan; 22(1):277-84. PubMed ID: 24315192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties.
    Conesa-Milián L; Falomir E; Murga J; Carda M; Marco JA
    Eur J Med Chem; 2019 May; 170():87-98. PubMed ID: 30878834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation as antiangiogenic agents of ureas derived from 3'-aminocombretastatin A-4.
    Conesa-Milián L; Falomir E; Murga J; Carda M; Marco JA
    Eur J Med Chem; 2019 Jan; 162():781-792. PubMed ID: 30502686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
    Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
    J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
    Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
    Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect.
    Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N
    Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of naphthalene imidazo[1,2-b]pyridazine hybrid derivatives as VEGFR selective inhibitors.
    Wang S; Gan L; Han L; Deng P; Li Y; He D; Chi H; Zhu L; Li Y; Long R; Gan Z
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400411. PubMed ID: 39008876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
    Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
    Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenyl and Diaryl Ureas with Thiazolo[5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors: Design, Synthesis and Biological Evaluation.
    Xue WJ; Deng YH; Yan ZH; Liu JP; Liu Y; Sun LP
    Chem Biodivers; 2019 Apr; 16(4):e1800493. PubMed ID: 30688404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
    Kim BH; Lee Y; Yoo H; Cui M; Lee S; Kim SY; Cho JU; Lee H; Yang BS; Kwon YG; Choi S; Kim TY
    Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: exploration of diverse hinge-binding fragments.
    Su P; Wang J; Shi Y; Pan X; Shao R; Zhang J
    Bioorg Med Chem; 2015 Jul; 23(13):3228-36. PubMed ID: 25982075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.